Skip to main contentSkip to navigationSkip to search

Press releases and news

2024

Camurus’ Nomination Committee appointed for the Annual General Meeting 2025

Camurus to present at Jefferies London Healtcare Conference

Camurus’ Interim Report Third Quarter 2024

Camurus improves ESG rating score by MSCI

Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly

Change in number of shares and votes in Camurus

EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease

Exercise in Camurus’ employee stock options program 2021/2024

Camurus recognized in Fortune’s Top 25 “Leading the charge: Spotlighting the 25 companies smashing the glass ceiling”

Camurus’ Interim Report Second Quarter 2024

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Change in number of shares and votes in Camurus

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

Camurus submits its first UN Global Compact Communication on Progress and renews the Nasdaq Transparency Partner certificate

Exercise of Camurus’ employee stock options program 2021/2024

Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027

Camurus to present at Jefferies 2024 Healthcare Conference New York

Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly

Resolutions at the annual general meeting 2024 in Camurus

Camurus’ Interim Report January-March 2024

Load more press releases

Subscribe

Get the latest news from Camurus

Subscribe to receive latest news from Camurus directly to your email. 

Information types

By subscribing to news from Camurus, you agree to our privacy policy.

Thank you. You will get an e-mail message to activate your subscription.